Widely Used Inhalers Won’t Cost More Than $35 a Month, AstraZeneca Says
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1. The inhalers treat asthma and chronic obstructive pulmonary disease, which combined affect roughly 41 million Americans and can make breathing extremely difficult.Do We Have to Send Humans to Mars for Exploration?The announcement comes after rival company Boehringer Ingelheim announced earlier this month that the cost of its…